This is a demo store. No orders will be fulfilled.

Fezagepras sodium - 10mM in DMSO, high purity , CAS No.1254472-97-3(DMSO)

    Grade & Purity:
  • 10mM in DMSO
In stock
Item Number
F656175
Grouped product items
SKU Size
Availability
Price Qty
F656175-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$198.90

Basic Description

Specifications & Purity 10mM in DMSO
Biochemical and Physiological Mechanisms Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Fezagepras sodium decreases renal, liver and pancreatic fibrosis. Fezagepras sodium exerts anti-fibrotic, anti-infla
Storage Temp Desiccated,Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description

Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 Fezagepras sodium decreases renal, liver and pancreatic fibrosis Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .

In Vitro

Fezagepras sodium (500 μM; 24 hours) inhibits TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation. ?\nFezagepras sodium (250 or 500 μM; 24 hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: HSCs Concentration: 250 or 500 µM Incubation Time: 24 hours Result: Inhibited TGF-β-activated HSC proliferation. TGF-β (10 ng/mL) increased HSC proliferation by 10%. Cell Cycle AnalysisCell Line: HSCs Concentration: 250 µM, 500 µM Incubation Time: 24 hours Result: Inhibited cell cycle progression.

In Vivo

Fezagepras sodium (100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improvea glucose tolerance in type 2 diabetes eNOS -/- db/db mice .· MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Type 2 diabetes eNOS -/- db/db mice Dosage: 100 mg/kg/day Administration: Given via daily gavage from 8-20 weeks Result: Compared with vehicle-treated mice, hyperglycemia was markedly decreased, and glucose tolerance was markedly improved.

IC50& Target:GPR40, GPR84

Names and Identifiers

Smiles CCCCCC1=CC(=CC=C1)CC(=O)[O-].[Na+]
Molecular Weight 228.26

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.